Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024

MADISON, Wis.–(BUSINESS WIRE)–Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts demonstrating the breadth of its Precision Oncology portfolio at the 2024 annual San Antonio Breast Cancer Symposium® (SABCS®) from December 10-13 in San Antonio, Texas. “Exact Sciences is committed to improving breast cancer care by providing actionable insights that support informed treatment decisions and help achieve the best outcomes fo